1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Sapien Maintains Big Benefit In Inoperable Patients At Two Years

Recent launch of the transcatheter aortic heart valve for patients too sick for open heart surgery may get a lift from data presented at TCT.

Edwards Lifesciences’ recent U.S. launch of its Sapien transcatheter aortic heart valve to treat patients who are not candidates for open heart surgery may get a lift from data presented at the Transcatheter Cardiovascular Therapeutics conference on Nov. 10.

Investigators reported at the San Francisco meeting two-year data from Edwards’ PARTNER/cohort B trial comparing the valve to best medical therapy in inoperable patients, just a week after Edwards announced FDA approval and the U.S. launch of Sapien for that population based on one-year data

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By Marion Webb

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.

More from R&D